Is trastuzumab a targeted therapy?

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is not a traditional chemotherapy drug as we know it, but a targeted therapy drug that has shown significant effects in cancer treatment. The drug cleverly combines an antibody (trastuzumab) that targets the HER2 receptor on the surface of cancer cells with a powerful cytotoxic drug (deruxtecan) to form a unique antibody-drug complex (ADC).

The mechanism of action of trastuzumab is that its antibody part accurately recognizes and binds to the HER2 receptor on the surface of cancer cells, and then uses the endocytosis of cells to bring the drug into the interior of the cancer cells. Once it enters the cell, the cytotoxic drugs it carries will be released to deliver a fatal blow to the cancer cells. This precise targeting allows trastuzumab to kill cancer cells while minimizing damage to normal cells, thus reducing the side effects of treatment.

Compared with traditional chemotherapy drugs, trastuzumab has higher specificity and lower toxicity. Not only can it locate and attack cancer cells more accurately, but it also puts a relatively smaller burden on the patient's body during treatment. This makes trastuzumab an ideal option, especially for cancer patients who have received other treatments that have not responded well, or who have developed resistance to traditional chemotherapy drugs.

Currently, trastuzumab is mainly used to treat malignant tumors such as HER2-positive breast cancer, non-small cell lung cancer, and gastric cancer. However, as research deepens and technology advances, we are expected to see its greater potential in the treatment of more types of cancer in the future. With its unique targeting mechanism and excellent clinical performance, the emergence of trastuzumab provides a new treatment option for cancer patients.